Cdk inhibitor and pharmaceutical uses thereof

HK40137824APending Publication Date: 2026-09-18ABBISKO THERAPEUTICS CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: HK62026126419
Authority / Receiving Office: HK · HK
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-11-11
Filing Date: 2026-07-21
Publication Date: 2026-09-18
Estimated Expiration: 2045-03-04

Application Information

Patent Timeline

11 Nov 2024

Priority

21 Jul 2026

Application

HK62026126419

18 Sep 2026

Publication

HK40137824A

IPC: C07D405/14; A61K31/435; A61K31/538; A61K31/395; A61K31/33; A61P35/00

Inventors: LI, ZHENG; DU, XINMING

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to a CDK kinase inhibitor and its pharmaceutical use. In particular, the present invention relates to a CDK inhibitor having the structure of formula (I) and its pharmaceutical composition, and its use as a CDK inhibitor and its use in the manufacture of a medicament for treating a cancer or a tumor at least partially associated with CDK. Wherein each substituent of formula (I) is the same as defined in the specification.

Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202580007353.0 (22) Application Date 2025.03.05 (66) Domestic Priority Data 202410263592.X 2024.03.07 CN 202410843814.5 2024.06.26 CN 202411608289.5 2024.11.11 CN (85) PCT International Application Entering National Phase Date 2026.06.10 (86) PCT International Application Application Data PCT / CN2025 / 080750 2025.03.05 (87) PCT International Application Publication Data WO2025 / 185655 ZH 2025.09.11 (71) Applicant: Shanghai Heyu Biomedical Technology Co., Ltd. Address: No. 3, Lane 898, Halei Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 201203, China (72) Inventors: Li Zheng, Du Xinming, Deng Haibing, Yu Hongping, Chen Zhui (74) Patent Agency: Shanghai Yiping Intellectual Property Agency Co., Ltd. 31266 Patent Attorneys: Ma Lihua, Xu Xun (51) Int.Cl. C07D 405 / 14 (2006.01) A61K 31 / 435 (2006.01) A61K 31 / 538 (2006.01) A61K 31 / 395 (2006.01) A61K 31 / 33 (2006.01) A61P 35 / 00 (2006.01) (54) Invention Title: A CDK Kinase Inhibitor and Its Pharmaceutical Use (57) Abstract: This invention relates to a CDK kinase inhibitor and its pharmaceutical use. In particular, this invention relates to a CDK inhibitor having the structure of formula (I) and pharmaceutical compositions thereof, as well as its use as a CDK inhibitor and its use in the preparation of medicaments for treating at least partially CDK-related cancers or tumors. The substituents in formula (I) are the same as defined in the specification. CN 122374307 A 2026.07.10 CN 1 22 37 43 07 A